1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 0000-0003-0475-438X Zerbe, O. Bardelli, M. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking Cell 1097-4172 171 229 241.e15 10.1016/j.cell.2017.09.002 28938115 A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. 2017 10.2210/pdb5omz/pdb pdb_00005omz 12479.393 Envelope Protein DOMAIN DIII, UNP residues 585-699 1 man polymer no no MDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKM MLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGK MDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKM MLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGK A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n ZIKV sample 1 115 64320 Zika virus (strain Mr 766) 562 Escherichia coli plasmid Biological sequence pET21a pdbx_nmr_software database_2 pdbx_database_status pdbx_nmr_spectrometer repository Initial release Data collection Data collection Database references Other 1 0 2017-10-04 1 1 2019-05-08 1 2 2023-06-14 _pdbx_nmr_software.name _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data _pdbx_nmr_spectrometer.model Solution structure of domain III (DIII)of Zika virus Envelope protein N PDBE Y PDBE 2017-08-02 REL REL REL REL structures with the lowest energy 100 20 isotropic 1 2D 1H-15N HSQC isotropic 2 2D 1H-13C HSQC aliphatic isotropic 2 2D 1H-13C HSQC aromatic isotropic 2 3D HNCO isotropic 2 3D HN(CA)CO isotropic 2 3D CBCA(CO)NH isotropic 2 3D HNCACB isotropic 2 3D HCCH-TOCSY isotropic 2 3D H(C)CH isotropic 2 3D HBHA(CO)NH isotropic 2 3D 1H-15N NOESY isotropic 2 3D 1H-13C NOESY aliphatic isotropic 2 3D 1H-13C NOESY aromatic isotropic 2 2D 1H-15N HSQC isotropic 2 3D 1H-15N NOESY isotropic 2 3D HNCO 800 uM 15N,13C 20 mM natural abundance 50 mM natural abundance 400 uM 2H,13C,15N 20 mM natural abundance 50 mM natural abundance 440 uM natural abundance 0.27 mM conditions_1 6.0 pH 1 atm 300 K further refinement in AMBER simulated annealing 1 lowest energy 800 uM 15N,13C ZIKA Envelope DIII, 20 mM sodium phosphate, 50 mM sodium chloride, 90% H2O/10% D2O sample for resonance assignment and structure determination sample_H2O 90% H2O/10% D2O solution 400 uM 2H,13C,15N ZIKA Envelope DIII, 20 mM sodium phosphate, 50 mM sodium chloride, 440 uM ZKA190 Fab, 90% H2O/10% D2O perdeuterated 13C,15N sample sample for mapping 90% H2O/10% D2O solution Bruker Biospin processing TopSpin 2.1 Keller and Wuthrich chemical shift assignment CARA 1.93 Guntert, Mumenthaler and Wuthrich structure calculation CYANA 3.97 600 Bruker AV-4 700 Bruker AVANCE MET 1 n 1 MET 1 A ASP 2 n 2 ASP 2 A LYS 3 n 3 LYS 3 A LEU 4 n 4 LEU 4 A ARG 5 n 5 ARG 5 A LEU 6 n 6 LEU 6 A LYS 7 n 7 LYS 7 A GLY 8 n 8 GLY 8 A VAL 9 n 9 VAL 9 A SER 10 n 10 SER 10 A TYR 11 n 11 TYR 11 A SER 12 n 12 SER 12 A LEU 13 n 13 LEU 13 A CYS 14 n 14 CYS 14 A THR 15 n 15 THR 15 A ALA 16 n 16 ALA 16 A ALA 17 n 17 ALA 17 A PHE 18 n 18 PHE 18 A THR 19 n 19 THR 19 A PHE 20 n 20 PHE 20 A THR 21 n 21 THR 21 A LYS 22 n 22 LYS 22 A ILE 23 n 23 ILE 23 A PRO 24 n 24 PRO 24 A ALA 25 n 25 ALA 25 A GLU 26 n 26 GLU 26 A THR 27 n 27 THR 27 A LEU 28 n 28 LEU 28 A HIS 29 n 29 HIS 29 A GLY 30 n 30 GLY 30 A THR 31 n 31 THR 31 A VAL 32 n 32 VAL 32 A THR 33 n 33 THR 33 A VAL 34 n 34 VAL 34 A GLU 35 n 35 GLU 35 A VAL 36 n 36 VAL 36 A GLN 37 n 37 GLN 37 A TYR 38 n 38 TYR 38 A ALA 39 n 39 ALA 39 A GLY 40 n 40 GLY 40 A THR 41 n 41 THR 41 A ASP 42 n 42 ASP 42 A GLY 43 n 43 GLY 43 A PRO 44 n 44 PRO 44 A CYS 45 n 45 CYS 45 A LYS 46 n 46 LYS 46 A VAL 47 n 47 VAL 47 A PRO 48 n 48 PRO 48 A ALA 49 n 49 ALA 49 A GLN 50 n 50 GLN 50 A MET 51 n 51 MET 51 A ALA 52 n 52 ALA 52 A VAL 53 n 53 VAL 53 A ASP 54 n 54 ASP 54 A MET 55 n 55 MET 55 A GLN 56 n 56 GLN 56 A THR 57 n 57 THR 57 A LEU 58 n 58 LEU 58 A THR 59 n 59 THR 59 A PRO 60 n 60 PRO 60 A VAL 61 n 61 VAL 61 A GLY 62 n 62 GLY 62 A ARG 63 n 63 ARG 63 A LEU 64 n 64 LEU 64 A ILE 65 n 65 ILE 65 A THR 66 n 66 THR 66 A ALA 67 n 67 ALA 67 A ASN 68 n 68 ASN 68 A PRO 69 n 69 PRO 69 A VAL 70 n 70 VAL 70 A ILE 71 n 71 ILE 71 A THR 72 n 72 THR 72 A GLU 73 n 73 GLU 73 A SER 74 n 74 SER 74 A THR 75 n 75 THR 75 A GLU 76 n 76 GLU 76 A ASN 77 n 77 ASN 77 A SER 78 n 78 SER 78 A LYS 79 n 79 LYS 79 A MET 80 n 80 MET 80 A MET 81 n 81 MET 81 A LEU 82 n 82 LEU 82 A GLU 83 n 83 GLU 83 A LEU 84 n 84 LEU 84 A ASP 85 n 85 ASP 85 A PRO 86 n 86 PRO 86 A PRO 87 n 87 PRO 87 A PHE 88 n 88 PHE 88 A GLY 89 n 89 GLY 89 A ASP 90 n 90 ASP 90 A SER 91 n 91 SER 91 A TYR 92 n 92 TYR 92 A ILE 93 n 93 ILE 93 A VAL 94 n 94 VAL 94 A ILE 95 n 95 ILE 95 A GLY 96 n 96 GLY 96 A VAL 97 n 97 VAL 97 A GLY 98 n 98 GLY 98 A GLU 99 n 99 GLU 99 A LYS 100 n 100 LYS 100 A LYS 101 n 101 LYS 101 A ILE 102 n 102 ILE 102 A THR 103 n 103 THR 103 A HIS 104 n 104 HIS 104 A HIS 105 n 105 HIS 105 A TRP 106 n 106 TRP 106 A HIS 107 n 107 HIS 107 A ARG 108 n 108 ARG 108 A SER 109 n 109 SER 109 A GLY 110 n 110 GLY 110 A SER 111 n 111 SER 111 A THR 112 n 112 THR 112 A ILE 113 n 113 ILE 113 A GLY 114 n 114 GLY 114 A LYS 115 n 115 LYS 115 A author_and_software_defined_assembly PISA 1 monomeric light scattering gel filtration 0 0 9230 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 A N THR 21 A N THR 21 A O GLU 35 A O GLU 35 A O ARG 63 A O ARG 63 A N ASP 85 A N ASP 85 A N ILE 95 A N ILE 95 A O ILE 102 A O ILE 102 1 A SER 10 -176.15 112.65 1 A ASN 68 -170.57 73.22 1 A THR 75 -53.46 171.98 1 A PRO 87 -69.79 -179.08 1 A LYS 100 -94.67 34.62 2 A ALA 39 -95.27 42.24 2 A ASP 42 -96.22 35.69 2 A ALA 52 -176.66 121.79 2 A PRO 60 -69.79 87.89 2 A ASN 68 -175.42 72.33 2 A GLU 76 -59.98 179.25 2 A PRO 87 -69.72 -172.22 2 A LYS 100 -95.66 34.39 2 A HIS 104 -163.68 114.82 3 A ALA 39 -96.90 38.78 3 A ASP 42 -173.74 107.83 3 A ALA 52 -171.85 106.99 3 A GLU 76 -54.51 172.37 3 A PRO 87 -69.77 -173.22 3 A LYS 100 -95.04 34.59 3 A SER 109 -171.52 -179.09 3 A ILE 113 -66.42 -175.84 4 A SER 10 -94.98 41.57 4 A THR 15 -151.47 82.60 4 A ALA 16 -62.85 -176.95 4 A ALA 39 -96.96 -68.59 4 A ASN 68 -178.94 71.85 4 A GLU 76 -59.34 178.37 4 A PRO 87 -69.72 -173.88 4 A LYS 100 -95.78 34.22 4 A THR 112 -126.29 -57.81 5 A LYS 7 -62.51 -70.64 5 A THR 41 -131.26 -39.80 5 A ASP 42 -161.51 101.52 5 A PRO 87 -69.70 -170.79 5 A LYS 100 -95.38 34.37 5 A HIS 105 -53.51 102.29 6 A ALA 25 -178.07 127.62 6 A THR 41 -95.19 34.27 6 A ASN 77 60.98 71.41 6 A PRO 87 -69.72 -171.39 6 A LYS 100 -94.61 35.13 6 A LYS 101 -49.94 166.37 6 A THR 112 -108.98 -73.54 7 A ALA 52 -173.16 -178.77 7 A PRO 60 -69.80 92.12 7 A ASN 68 -174.06 73.40 7 A THR 75 -53.32 172.36 7 A LYS 100 -95.97 34.24 8 A LYS 3 -169.38 114.16 8 A GLN 50 -171.20 147.78 8 A ASN 68 -172.55 74.02 8 A LYS 100 -95.76 34.30 8 A SER 109 -170.09 -177.95 9 A SER 10 -171.04 121.73 9 A ALA 16 -170.42 134.97 9 A ALA 39 -101.46 71.30 9 A ASN 68 -176.52 72.50 9 A MET 80 -160.48 117.95 9 A PRO 87 -69.75 -171.91 9 A SER 109 -109.14 -63.75 9 A THR 112 -105.22 44.23 10 A ASP 2 -115.23 52.59 10 A ALA 25 -172.75 129.75 10 A ALA 39 -95.81 52.16 10 A ASP 42 -160.19 98.09 10 A ASN 68 -178.83 69.05 10 A GLU 76 -63.44 -179.11 10 A PRO 87 -69.74 -171.54 10 A LYS 100 -95.25 34.39 10 A SER 109 -137.55 -59.99 10 A THR 112 -109.24 40.46 11 A LYS 7 -60.70 -178.09 11 A SER 10 -175.05 134.57 11 A ALA 25 -178.25 124.08 11 A THR 41 -95.51 35.78 11 A ASP 42 -120.16 -67.50 11 A ALA 52 -175.41 147.82 11 A ASN 68 -175.90 68.46 11 A GLU 76 -57.12 176.28 11 A PRO 87 -69.76 -172.23 11 A LYS 100 -94.91 34.55 12 A ALA 25 -172.67 142.96 12 A GLN 50 -173.93 143.51 12 A THR 66 -54.76 174.16 12 A ASN 68 -176.94 73.74 12 A MET 80 -173.66 123.32 12 A PRO 87 -69.76 -170.90 12 A HIS 104 -164.78 116.54 13 A LEU 4 -117.22 62.50 13 A SER 12 -174.04 -178.76 13 A THR 41 -95.22 34.91 13 A ALA 52 -169.98 100.51 13 A ASN 68 -165.08 73.74 13 A THR 75 -53.01 171.77 13 A PRO 87 -69.78 -170.92 13 A LYS 100 -95.41 34.35 14 A ALA 25 -171.14 119.78 14 A ALA 39 -115.64 56.98 14 A THR 41 -98.26 43.15 14 A ASP 42 -108.45 42.53 14 A ALA 52 -167.65 118.94 14 A THR 66 -56.84 174.11 14 A ASN 68 -179.05 73.62 14 A PRO 87 -69.75 -171.32 14 A LYS 100 -95.37 34.50 15 A ALA 16 -63.00 -177.63 15 A ASP 42 62.29 61.44 15 A THR 66 -55.49 174.61 15 A ASN 68 -167.19 74.26 15 A GLU 76 -58.68 -177.34 15 A PRO 87 -69.73 -170.84 15 A SER 91 -131.09 -75.04 15 A LYS 100 -94.53 34.57 16 A THR 15 -151.03 80.70 16 A ALA 39 -78.24 -75.71 16 A PRO 60 -69.76 99.24 16 A THR 75 -59.67 176.64 16 A MET 80 -169.10 118.81 16 A PRO 87 -69.66 -170.86 16 A LYS 100 -95.91 34.34 17 A PRO 60 -69.80 96.82 17 A ASN 68 -175.40 73.33 17 A PRO 87 -69.74 -175.05 17 A LYS 100 -95.62 34.37 18 A ALA 39 -96.64 41.94 18 A THR 41 -54.04 -70.87 18 A ASP 42 -161.92 102.94 18 A LEU 64 -116.49 69.72 18 A ILE 65 -121.01 -59.02 18 A GLU 76 -58.86 -179.49 18 A PRO 87 -69.76 -177.53 18 A PHE 88 -52.12 103.55 18 A SER 91 -93.77 -74.80 18 A LYS 100 -94.39 34.69 19 A ASP 2 -57.12 175.25 19 A ASN 68 -153.81 73.44 19 A THR 75 -56.82 178.43 19 A PRO 87 -69.74 -171.36 19 A LYS 100 -94.33 34.42 20 A ALA 16 -57.52 174.84 20 A ALA 25 -173.12 125.14 20 A ALA 52 -174.61 144.48 20 A ASN 68 -176.08 73.00 20 A GLU 76 -59.16 175.64 20 A PRO 87 -69.74 -177.02 20 A LYS 100 -93.78 35.38 20 A LYS 101 -49.41 165.83 N Solution structure of domain III (DIII)of Zika virus Envelope protein 1 N N VIRAL PROTEIN ZIKA virus Envelope protein domain, VIRAL PROTEIN, ZIKV A GLY 43 A GLY 43 1 A PRO 44 A PRO 44 0.12 A GLY 43 A GLY 43 2 A PRO 44 A PRO 44 0.02 A GLY 43 A GLY 43 3 A PRO 44 A PRO 44 0.01 A GLY 43 A GLY 43 4 A PRO 44 A PRO 44 -0.02 A GLY 43 A GLY 43 5 A PRO 44 A PRO 44 0.12 A GLY 43 A GLY 43 6 A PRO 44 A PRO 44 0.03 A GLY 43 A GLY 43 7 A PRO 44 A PRO 44 -0.04 A GLY 43 A GLY 43 8 A PRO 44 A PRO 44 0.09 A GLY 43 A GLY 43 9 A PRO 44 A PRO 44 0.14 A GLY 43 A GLY 43 10 A PRO 44 A PRO 44 0.04 A GLY 43 A GLY 43 11 A PRO 44 A PRO 44 -0.06 A GLY 43 A GLY 43 12 A PRO 44 A PRO 44 0.02 A GLY 43 A GLY 43 13 A PRO 44 A PRO 44 0.02 A GLY 43 A GLY 43 14 A PRO 44 A PRO 44 0.08 A GLY 43 A GLY 43 15 A PRO 44 A PRO 44 0.16 A GLY 43 A GLY 43 16 A PRO 44 A PRO 44 0.12 A GLY 43 A GLY 43 17 A PRO 44 A PRO 44 -0.16 A GLY 43 A GLY 43 18 A PRO 44 A PRO 44 0.00 A GLY 43 A GLY 43 19 A PRO 44 A PRO 44 -0.08 A GLY 43 A GLY 43 20 A PRO 44 A PRO 44 0.11 A0A1V0E2E5_ZIKV UNP 1 585 A0A1V0E2E5 MDKLRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVITESTENSKM MLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGK 585 699 5OMZ 1 115 A0A1V0E2E5 A 1 1 115 2 2 2 anti-parallel anti-parallel anti-parallel A PHE 20 A PHE 20 A LYS 22 A LYS 22 A GLU 35 A GLU 35 A VAL 36 A VAL 36 A ARG 63 A ARG 63 A LEU 64 A LEU 64 A LEU 84 A LEU 84 A ASP 85 A ASP 85 A VAL 94 A VAL 94 A ILE 95 A ILE 95 A ILE 102 A ILE 102 A THR 103 A THR 103